Dexasone
Precursor Lymphoblastic Lymphoma/Leukemia
Explore 20 assets in Precursor Lymphoblastic Lymphoma/Leukemia →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06387121CT.gov Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | — | Recruiting | — | — | — |
NCT05660473CT.gov Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT03888534CT.gov Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) | — | Withdrawn | — | — | — |
NCT01331590CT.gov Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Precursor Lymphoblastic Lymphoma/Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Institute of Hematology & Blood Diseases Hospital, China | P2 | B · 63 |
| Lidocaine | CAMC Health System | P4 | BB |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Etoposide | Asan Medical Center | P2 | B |
| Adriamycin | Janssen Research & Development, LLC | P2 | B |
| Cytarabine | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Mercaptopurine Anhydrous | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Prednisone | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Daratumumab | Janssen Research & Development, LLC | P2 | B |
+25 more in the Precursor Lymphoblastic Lymphoma/Leukemia cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Precursor Lymphoblastic Lymphoma/Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-precursor-lymphoblastic-lymphomaleukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →